Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Biologists have discovered genetic material that may help to explain part of how our immune defense is triggered. Dubbing it THRIL, they say it could be targeted in the development of treatments against inflammatory diseases such as Kawasaki disease, rheumatoid arthritis and inflammatory bowel disease.The researchers have discovered a new molecule that forms when the immune response is triggered by pathogens - such as disease-causing bacteria and viruses.
The THRIL molecule, they found, is involved when white blood cells called macrophages are stimulated as part of the cascade of immunity that defends the body.
The molecule, say the scientists from San Diego, CA, and Ontario, Canada, helps regulate the immune response and shows an association with Kawasaki disease, the immune disorder that the medical researchers focused on for their study - a rare childhood disease that involves inflammation of the blood vessels.
The lead study author, Tariq Rana, PhD, is from the Sanford-Burnham Medical Research Institute in Ontario, which also has a base in Orlando, FL.
He says the work builds on the knowledge of RNA genetic material and its role in our innate response to microbial threats.
Dr. Rana, who is a professor in the Sanford Children's Health Research Center and director of the RNA Biology Program at Sanford-Burnham, says: "For some time we have known that noncoding regions of RNA play important roles in regulating the immune response to microbial pathogens."
"When we realized that THRIL functioned to control the TNF-alpha gene, we wanted to see if it mirrors the progression in inflammatory diseases."
The research paper introduces TNF-alpha as "a critical cytokine released early in the innate immune response."
In other words, it promotes inflammation. So a molecule that affects TNF-alpha levels may be important to the understanding of inflammatory disease.
Dr. Rana's research team measured THRIL levels in samples taken from children with different stages of Kawasaki disease.
Collaborating with clinician Dr. Jane Burns - a professor of pediatrics at the University of California and the Rady Children's Hospital in San Diego, CA - the team found that the THRIL levels were lowest during the acute stage of the disease, when TNF-alpha levels are at their highest.
The researchers conclude:
"The findings suggest that THRIL could be a novel biomarker for immune activation and a potential target for inflammatory diseases."
Summarizing the significance of their research, the authors say in the scientific paper that the new molecule plays an important role in healthy (physiological) inflammatory immune responses as well as being involved with pathological responses.
The study is published online in the Proceedings of the National Academy of Sciences. The authors named the molecule THRIL after "TNF-alpha- and hnRNPL-related immunoregulatory lincRNA."
Written by Markus MacGill
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Lia Z, Chaoa T-C, Chang K-Y, and others. Proceedings of the National Academy of Sciences of the United States of America, published online before print December 26, 2013 (DOI: 10.1073/pnas.1313768111). Full-text PDF; abstract.
Visit our Immune System / Vaccines category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
MacGill, Markus. "Molecular researchers find new key to inflammatory diseases." Medical News Today. MediLexicon, Intl., 30 Dec. 2013. Web.
20 Apr. 2014. <http://www.medicalnewstoday.com/articles/270651>
MacGill, M. (2013, December 30). "Molecular researchers find new key to inflammatory diseases." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/270651.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.